1.Effect and nursing on application of hypophysin to refractory hypotension after open heart operation
Wei-Qun WENG ; Xun ZHUANG ; Li-Hua YAN
Chinese Journal of Modern Nursing 2010;16(33):4004-4006
Objective To evaluate the effect of hypophysin on refractory hypotension after open heart operation and nursing interventions. Methods 12 patients with refractory hypotension( mean arterial pressure pumped without added the dose of catecholamine. Observed and compared the heart rate , mean arterial pressure, shock index, urinary volume, and the dose of catecholamine at baseline and 0.5,2, 4,12,24 h after hypophysin. Results The mean arterial pressure and urinary volume changed significantly compared with baseline( P <0. 05 ). The heart rate, MAP, shock index, urinary volume, and the dose of catecholamines were observed after 2h, which had significant different between every point after hypophysin used and baseline( P <0. 05 ). All patients survived. Conclusions The low dose of hypophysin can reverse refractory hypotension rapidly and safety. Every vital sign should be monitored exactly and adjusted the dose of vasopressors immediately according to the variation of blood pressure. The drug adverse reaction should be observed intensively and treated immediately.
2.Expression of Bcl-2 and Bax proteins in rat liver fibrosis model and the role of IFN-gamma.
Jun TAO ; Wei-min CAI ; Liang-wei LU ; Qun-wei CHEN ; Hong-lei WENG ; Yong-sheng ZHANG
Chinese Journal of Hepatology 2003;11(11):669-672
OBJECTIVETo study the expression of Bcl-2 and Bax in rat liver fibrosis model induced by CCl4 and the role of IFN-gamma.
METHODSLiver fibrosis was induced in rats by subcutaneous injection of CCl4. The rats were divided into fibrosis model group, Bie-Jia-Ruan-Gan-Tablet treatment group and IFN-gamma treatment group (0.2 MU.kg.d, i. m. for 12 weeks), and another 10 rats without any treatment were used as normal control. Bcl-2 and Bax proteins expression were detected by immunohistochemistry.
RESULTSBcl-2 was expressed weakly in the homogenate of hepatocytes and hepatic sinusoid in normal control rats, and it was expressed stronger in fibrous septae, portal area, hepatic sinusoid, the homogenate and membrane of hepatocytes and central vein in fibrosis model rats (3.87%+/-2.37% vs 9.46%+/-4.29%, t=2.83, P<0.05). Bax was expressed slightly in central vein and the hepatic sinusoid around, and it was expressed stronger in the homogenate of hepatocytes, hepatic sinusoid, fibrous septae, membrane of hepatocytes and epithelial cells of bile duct (3.50%+/-1.88% vs 9.80%+/-3.75%, t=3.72, P<0.01). Compared with that in fibrosis model rats, the expression of Bax was significantly lower in rats treated with IFN-gamma (9.80%+/-3.75% vs 5.85%+/-2.35%, t=2.98, P<0.01), but the expression of Bcl-2 was not significantly different (t=1.49, P>0.05), however it was significantly lower in fibrous septae in IFN-gamma-treated group than in model group (6.58%+/-4.13% vs 9.46%+/-4.29%, t=2.80, P<0.05).
CONCLUSIONThe expression of Bcl-2 and Bax increases in liver fibrosis model rats, and IFN-gamma can promote myofibroblasts apoptosis
Animals ; Apoptosis ; Disease Models, Animal ; Female ; Gene Expression ; Interferon-gamma ; pharmacology ; Liver Cirrhosis ; metabolism ; Male ; Proto-Oncogene Proteins ; metabolism ; Proto-Oncogene Proteins c-bcl-2 ; metabolism ; Rats ; Rats, Sprague-Dawley ; Recombinant Proteins ; pharmacology ; bcl-2-Associated X Protein
3.Regimen containing perarubicin for the treatment of newly diagnosed young patients with acute myeloid leukemia
Zhong LI-YE ; Li QUN-HUA ; Huang ZI-LUN ; Lin WEI ; Lu ZE-SHENG ; Weng JIAN-YU ; Wu SUI-JING ; Du XIN
Chinese Journal of Cancer 2009;28(6):619-625
Background and Objective: Chemotherapy regimen containing anthracyclines has been used as the standard treatment for acute myeloid leukemia (AML). This study was to compare the efficacy and toxicity of the chemotherapy regimen containing perarubicin (THP) with that containing mitoxantrone (MIT) for young patients with newly diagnosed AML. Methods: A total of 129 patients with newly diagnosed AML, aged 16 to 60 years olds, were assigned for induction chemotherapy containing one to two courses with standard-dose cytarabine (Ara-C) and an anthracycline antibiotic, THP or MIT. When complete remission was achieved after induction therapy, the patients received two courses of consolidation therapy identical to the induction regimen. From then, the patients were alternately given four courses of consolidation therapy consisting of Ara-C/I-HP or Ara-C/MIT every three weeks. Maintenance treatment continued for three years when patients were in continuous complete remission (CCR). Results: Twenty-six out of 42 patients (61.90%) receiving THP therapy, and 48 out of 73 patients (65.75%) treated by MIT achieved CR (P>0.05). Nine (34.61%) and 11 (22.92%) out of CR patients treated by THP and MIT, respectively, relapsed within one year (P= 0.28). Moreover, the incidences of toxicities, such as infection, nausea/ vomiting and cardiac events, were similar in these two groups (P>0.05) except for alopecie, which was 26.19% in the THP group compared to 42.47% in the MIT group (P<0.01). Conclusions: Regimen containing THP plus Ara-C can be used for young adults with newly diagnosed AML for remission induction, but it is not superior to the regimen with MIT. Consolidation chemotherapy with THP or MIT is feasible for young adults with AML after CR.
4.Looking back to 2023: advancement in epilepsy diagnosis and treatment
Qun WANG ; Shiwen WENG ; Huajun YANG ; Wei SHAN
Chinese Journal of Neurology 2024;57(10):1037-1044
In 2023, significant progress was achieved in both basic and clinical research in the field of epilepsy, opening up new avenues and providing valuable insights which advance understanding of epilepsy. These advancements encompassed research on the mechanism of anti-epileptic seizure drugs, genomic research on the causes of epilepsy, cell gene therapy, exploration of the relationship between epilepsy and cognition, comparative research on the treatment of children and idiopathic epilepsy, as well as the development of new drugs and devices. These substantial progresses have contributed to a more comprehensive understanding of the complexity of epilepsy, provided identified targets for further basic research, and provided guidance for clinical diagnosis and treatment.
5.Application of holographic image navigation in urological laparoscopic and robotic surgery
Gang ZHU ; Jinchun XING ; Guobin WENG ; Zhiquan HU ; Ningchen LI ; He ZHU ; Pingsheng GAO ; Zhihua WANG ; Weizhi ZHU ; Kai ZHANG ; Hongbo LI ; Zhun WU ; Rui ZHU ; Xifeng WEI ; Yanan WANG ; Qun XIE ; Bing FU ; Xinghuan WANG ; Lin QI ; Xin YAO ; Tiejun PAN ; Delin WANG ; Nan LIU ; Jianguang QIU ; Jianggen YANG ; Bao ZHANG ; Zhuowei LIU ; Hui HAN ; Gang LI ; Bin ZHANG ; Manli NA ; Jingjing LU ; Lei WANG ; Zichen ZHAO ; Yanqun NA
Chinese Journal of Urology 2020;41(2):131-137
Objective To evaluate the clinical value of holographic image navigation in urological laparoscopic and robotic surgery.Methods The data of patients were reviewed retrospectively for whom accepted holographic image navigation laparoscopic and robotic surgery from Jan.2019 to Dec.2019 in Beijing United Family Hospital and other 18 medical centers,including 78 cases of renal tumor,2 cases of bladder cancer,2 cases of adrenal gland tumor,1 cases of renal cyst,1 case of prostate cancer,1 case of sweat gland carcinoma with lymph node metastasis,1 case of pelvic metastasis after radical cystectomy.All the patients underwent operations.In the laparoscopic surgery group,there were 27 cases of partial nephrectomy,1 case of radical prostatectomy,2 cases of radical cystectomy and 2 cases of adrenalectomy.In the da Vinci robotic surgery group of 54 cases,there were 51 cases of partial nephrectomy,1 case of retroperitoneal lymph node dissection,1 case of retroperitoneal bilateral renal cyst deroofing and 1 case of resection of pelvic metastasis.There were 41 partial nephrectomy patients with available clinical data for statistic,with a median age of 53.5 years (range 24-76),including 26 males and 15 females.The median R.E.N.A.L score was 7.8 (range 4-11).Before the operation,the engineers established the holographic image based on the contrast CT images and reports.The surgeon applied the holographic image for preoperative planning.During the operation,the navigation was achieved by real time fusing holographic images with the laparoscopic surgery images in the screen.Results All the procedures had been complete uneventfully.The holographic images helped surgeon in understanding the visual three-dimension structure and relation of vessels supplying tumor or resection tissue,lymph nodes and nerves.By manipulating the holographic images extracorporeally,the fused image guide surgeons about location vessel,lymph node and other important structure and then facilitate the delicate dissection.For the 41 cases with available clinical data including 23 cases of robotic-assisted partial nephrectomy and 18 cases of laparoscopic nephrectomy,the median operation time was 140 (range 50-225) min,the median warm ischemia time was 23 (range 14-60) min,the median blood loss was 80(range 5-1 200) ml.In the robotic surgery group,the median operation time was 140 (range 50-215)min,the median warm i schemia time was 21 (range 17-40)min,the median blood loss was 150(range 30-1 200)ml.In the laparoscopic surgery group,the median operation time was 160(range 80-225)min,the median warm ischemia time was 25 (range 14-60)min,the median blood loss was 50 (range 5-1 200) ml.All the patients had no adjacent organ injury during operation.There were 2 cases with Clavien Ⅱ complications.One required transfusion and the other one suffered hematoma post-operation.However,the tumors were located in the renal hilus for these 2 cases and the R.E.N.A.L scores were both 11.Conclusions Holographic image navigation can help location and recognize important anatomic structures during the surgical procedures..This technique will reduce the tissue injury,decrease the complications and improve the success rate of surgery.
6.Consensus for the management of severe acute respiratory syndrome.
Nanshang ZHONG ; Yanqing DING ; Yuanli MAO ; Qian WANG ; Guangfa WANG ; Dewen WANG ; Yulong CONG ; Qun LI ; Youning LIU ; Li RUAN ; Baoyuan CHEN ; Xiangke DU ; Yonghong YANG ; Zheng ZHANG ; Xuezhe ZHANG ; Jiangtao LIN ; Jie ZHENG ; Qingyu ZHU ; Daxin NI ; Xiuming XI ; Guang ZENG ; Daqing MA ; Chen WANG ; Wei WANG ; Beining WANG ; Jianwei WANG ; Dawei LIU ; Xingwang LI ; Xiaoqing LIU ; Jie CHEN ; Rongchang CHEN ; Fuyuan MIN ; Peiying YANG ; Yuanchun ZHANG ; Huiming LUO ; Zhenwei LANG ; Yonghua HU ; Anping NI ; Wuchun CAO ; Jie LEI ; Shuchen WANG ; Yuguang WANG ; Xioalin TONG ; Weisheng LIU ; Min ZHU ; Yunling ZHANG ; Zhongde ZHANG ; Xiaomei ZHANG ; Xuihui LI ; Wei CHEN ; Xuihua XHEN ; Lin LIN ; Yunjian LUO ; Jiaxi ZHONG ; Weilang WENG ; Shengquan PENG ; Zhiheng PAN ; Yongyan WANG ; Rongbing WANG ; Junling ZUO ; Baoyan LIU ; Ning ZHANG ; Junping ZHANG ; Binghou ZHANG ; Zengying ZHANG ; Weidong WANG ; Lixin CHEN ; Pingan ZHOU ; Yi LUO ; Liangduo JIANG ; Enxiang CHAO ; Liping GUO ; Xuechun TAN ; Junhui PAN ; null ; null
Chinese Medical Journal 2003;116(11):1603-1635